POSITIVE RESULTS OF TESMILIFENE STUDY PUBLISHED

YM BioSciences has announced the publication of a research paper in the November 2005 issue of the Journal of Urology that reports results from a Phase II trial of tesmilifene plus mixantrone/prednisone for the treatment of hormone-refractory prostate cancer. The paper reported that the prostate specific antigen decrease and reduction of symptoms observed with tesmilifene plus mitoxantrone/prednisone compare favorably to those of mitoxantrone/prednisone and docetaxel/estramustine in the literature, and that the two-year survival rate of 21 percent mandates further assessment in a Phase III trial.

The trial enrolled a total of 29 patients with progressive hormone-refractory prostate cancer who received 5.3 mg/kg of tesmilifene intravenously every three weeks, 12 mg/m2 mitoxantrone intravenously every week and 5 mg prednisone orally twice daily.